Table 2.
Response rates
| Entire study cohort (N = 16) | Monotherapy |
Monotherapy + induction∗ |
||||
|---|---|---|---|---|---|---|
| Day 35 |
Day 77 |
Day 77 |
||||
| n | % | n | % | n | % | |
| CR | 3 | 18.8 | 3 | 18.8 | 6 | 37.5 |
| PR | 2 | 13.5 | 0 | 0 | 1 | 6.3 |
| No response† | 11 | 67.7 | 13 | 81.2 | 9 | 56.2 |
| ORR (CR + PR) | 5 | 31.3 | 3 | 18.8 | 7 | 43.8 |
∗
Induction therapies (n = 6) included fludarabine, cytarabine, and granulocyte colony-stimulating factor (n = 3); decitabine and venetoclax (n = 2); mitoxantrone, etoposide, and cytarabine (n = 1).
†
Includes progression, nonresponse/SD, not assessed, or received other leukemia-directed therapy.